Autor: "Desai, J" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Autorzy:: Segelov E; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia. .
Waring P; University of Melbourne, Melbourne, Australia.
Desai J; Royal Melbourne Hospital, Melbourne, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia.
Wilson K; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Gebski V; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Thavaneswaran S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
Elez E; Vall d'Hebron University Hospital, Barcelona, Spain.
Underhill C; Border Medical Oncology, Albury-Wodonga, Australia.
Pavlakis N; Northern Cancer Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia.
Chantrill L; Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, Australia.; Kinghorn Cancer Centre, Sydney, Australia.
Nott L; Royal Hobart Hospital, Hobart, Australia.
Jefford M; Peter MacCallum Cancer Centre, Melbourne, Australia.
Khasraw M; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.; Andrew Love Cancer Centre, Geelong, Australia.
Day F; Calvary Mater Newcastle, University of Newcastle, Newcastle, Australia.
Wasan H; Hammersmith Hospital, London, UK.
Ciardiello F; Oncologia Medica, Seconda Università degli Studi di Napoli, Naples, Italy.
Karapetis C; Flinders Medical Centre, Adelaide, Australia.
Joubert W; Princess Alexandra Hospital, Brisbane, Australia.
van Hazel G; Sir Charles Gairdner Hospital, Perth, Australia.
Haydon A; Alfred Hospital, Melbourne, Australia.
Price T; Queen Elizabeth Hospital, Lyell McEwin Hospital, Adelaide, Australia.
Tejpar S; University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
Tebbutt N; Austin Hospital, Melbourne, Australia.
Shapiro J; Cabrini Hospital, Melbourne, Australia.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2016 May 31; Vol. 16, pp. 339. Date of Electronic Publication: 2016 May 31.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:: Research Design*
Antineoplastic Agents/*administration & dosage
Camptothecin/*analogs & derivatives
Cetuximab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Activating Transcription Factor 6 ; Antineoplastic Agents/adverse effects ; Basic-Leucine Zipper Transcription Factors/genetics ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Cetuximab/adverse effects ; Class I Phosphatidylinositol 3-Kinases/genetics ; Colorectal Neoplasms/genetics ; Disease-Free Survival ; GTP Phosphohydrolases/genetics ; Humans ; Irinotecan ; Membrane Proteins/genetics ; Mutation ; Prospective Studies ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.
Autorzy:: Turner NH; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Wong HL; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Field K; Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Wong R; Department of Medical Oncology, Eastern Health, Melbourne, Victoria, Australia.; Eastern Health Medical School, Monash University, Melbourne, Victoria, Australia.
Shapiro J; Cabrini Health, Melbourne, Victoria, Australia.
Yip D; The Canberra Hospital, Canberra, Australian Capital Territory, Australia.; Calvary Hospital, Canberra, Australian Capital Territory, Australia.; ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia.
Nott L; Royal Hobart Hospital, Hobart, Tasmania, Australia.
Tie J; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Medical Oncology, Western Hospital, Melbourne, Victoria, Australia.
Kosmider S; Department of Medical Oncology, Western Hospital, Melbourne, Victoria, Australia.
Tran B; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Medical Oncology, Western Hospital, Melbourne, Victoria, Australia.
Desai J; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
McKendrick J; Department of Medical Oncology, Eastern Health, Melbourne, Victoria, Australia.
Zimet A; Epworth Hospital, Melbourne, Victoria, Australia.
Richardson G; Cabrini Health, Melbourne, Victoria, Australia.
Iddawela M; Goulburn Valley Health, Shepparton, Victoria, Australia.; University of Melbourne Rural Health Academic Centre, Shepparton, Victoria, Australia.
Gibbs P; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; BioGrid Australia, Melbourne, Victoria, Australia.; Royal Hobart Hospital, Hobart, Tasmania, Australia.; Pokaż więcej
Źródło:: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2015 Sep; Vol. 11 (3), pp. 262-71. Date of Electronic Publication: 2015 Apr 14.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Colorectal Neoplasms/*therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Australia ; Colorectal Neoplasms/pathology ; Disease Management ; Female ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Quality Indicators, Health Care ; Young Adult